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Cell culture-adaptive mutations within the hepatitis C virus (HCV) E2 glycoprotein have been widely
reported. We identify here a single mutation (N415D) in E2 that arose during long-term passaging of HCV
strain JFH1-infected cells. This mutation was located within E2 residues 412 to 423, a highly conserved region
that is recognized by several broadly neutralizing antibodies, including the mouse monoclonal antibody (MAb)
AP33. Introduction of N415D into the wild-type (WT) JFH1 genome increased the affinity of E2 to the CD81
receptor and made the virus less sensitive to neutralization by an antiserum to another essential entry factor,
SR-BI. Unlike JFH1WT, the JFH1N415D was not neutralized by AP33. In contrast, it was highly sensitive to
neutralization by patient-derived antibodies, suggesting an increased availability of other neutralizing epitopes
on the virus particle. We included in this analysis viruses carrying four other single mutations located within
this conserved E2 region: T416A, N417S, and I422L were cell culture-adaptive mutations reported previously,
while G418D was generated here by growing JFH1WT under MAb AP33 selective pressure. MAb AP33 neu-
tralized JFH1T416A and JFH1I422L more efficiently than the WT virus, while neutralization of JFH1N417S and
JFH1G418D was abrogated. The properties of all of these viruses in terms of receptor reactivity and neutral-
ization by human antibodies were similar to JFH1N415D, highlighting the importance of the E2 412-423 region
in virus entry.
Hepatitis C virus (HCV), which belongs to the Flaviviridae
family, has a positive-sense single-stranded RNA genome en-
coding a polyprotein that is cleaved by cellular and viral pro-
teases to yield mature structural and nonstructural proteins.
The structural proteins consist of core, E1 and E2, while the
nonstructural proteins are p7, NS2, NS3, NS4A, NS4B, NS5A,
and NS5B (42). The hepatitis C virion comprises the RNA
genome surrounded by the structural proteins core (nucleo-
capsid) and E1 and E2 (envelope glycoproteins). The HCV
glycoproteins lie within a lipid envelope surrounding the nu-
cleocapsid and play a major role in HCV entry into host cells
(21). The development of retrovirus-based HCV pseudopar-
ticles (HCVpp) (3) and the cell culture infectious clone JFH1
(HCVcc) (61) has provided powerful tools to study HCV entry.
HCV entry is initiated by the binding of virus particles to
attachment factors which are believed to be glycosaminogly-
cans (2), low-density lipoprotein receptor (41), and C-type
lectins such as DC-SIGN and L-SIGN (12, 37, 38). Upon
attachment at least four entry factors are important for particle
internalization. These include CD81 (50), SR-BI (53) and the
tight junction proteins claudin-1 (15) and occludin (6, 36, 51).
CD81, a member of the tetraspanin family, is a cell surface
protein with various functions including tissue differentiation,
cell-cell adhesion and immune cell maturation (34). It consists
of a small and a large extracellular loop (LEL) with four
transmembrane domains. Viral entry is dependent on HCV E2
binding to the LEL of CD81 (3, 50). The importance of HCV
glycoprotein interaction with CD81 is underlined by the fact
that many neutralizing antibodies compete with CD81 and act
in a CD81-blocking manner (1, 5, 20, 45).
SR-BI is a multiligand receptor expressed on liver cells and
on steroidogenic tissue. It binds to high-density lipoproteins
(HDL), low-density lipoproteins (LDL), and very low-density
lipoproteins (VLDL) (31). The SR-BI binding site is mapped
to the hypervariable region 1 (HVR-1) of HCV E2 (53). SR-BI
ligands, such as HDL and oxidized LDL have been found to
affect HCV infectivity (4, 14, 58–60). Indeed, HDL has been
shown to enhance HCV infection in an SR-BI-dependent man-
ner (4, 14, 58, 59). Antibodies against SR-BI and knockdown of
SR-BI in cells result in a significant inhibition of viral infection
in both the HCVpp and the HCVcc systems (5, 25, 32).
Although clearly involved in entry and immune recognition,
the more downstream function(s) of HCV glycoproteins are
poorly understood, as their structure has not yet been solved.
Nonetheless, mutational analysis and mapping of neutralizing
antibody epitopes have delineated several discontinuous re-
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gions of E2 that are essential for HCV particle binding and
entry (24, 33, 45, 47). One of these is a highly conserved se-
quence spanning E2 residues 412 to 423 (QLINTNGSWHIN).
Several broadly neutralizing monoclonal antibodies (MAbs)
bind to this epitope. These include mouse monoclonal anti-
body (MAb) AP33, rat MAb 3/11, and the human MAbs e137,
HCV1, and 95-2 (8, 16, 44, 45, 49). Of these, MAbs AP33, 3/11,
and e137 are known to block the binding of E2 to CD81.
Cell culture-adaptive mutations within the HCV glycopro-
teins are valuable for investigating the virus interaction(s) with
cellular receptors (18). In the present study, we characterize an
asparagine-to-aspartic acid mutation at residue 415 (N415D)
in HCV strain JFH1 E2 that arose during the long-term pas-
saging of infected human hepatoma Huh-7 cells. Alongside
N415D, we also characterize three adjacent cell culture adap-
tive mutations reported previously and a novel substitution
generated in the present study by propagating virus under
MAb AP33 selective pressure to gain further insight into the
function of this region of E2 in viral infection.
MATERIALS AND METHODS
Cell culture and antibodies. Human embryo kidney (HEK)-293T cells (ATCC
CRL-1573) and the human hepatoma Huh-7 cells (43) were grown in Dulbecco
modified Eagle medium (Invitrogen, United Kingdom) supplemented with 10%
fetal calf serum, 100 U of penicillin/ml, 100 g of streptomycin/ml, 10 mM
HEPES, 0.1 mM nonessential amino acids, and 2 mM glutamine. The secreted
alkaline phosphatase (SEAP) reporter cell line Huh7J-20 was described previ-
ously (23).
The anti-E2 MAbs AP33, CBH-4B, CBH-5, and HC-11 and the purified
polyclonal immunoglobulins (IgGs) from an uninfected individual (IgG20) and
HCV-infected patients (IgG2, IgG4, IgG17, and IgG19) have been described
previously (11, 19, 20, 45). The anti-E2 MAb 3/11 (16), the anti-NS5A MAb 9E10
(35), and the sheep anti-NS5A antiserum (39) were kindly provided by J.
McKeating, C. M. Rice, and M. Harris, respectively. The anti-CD81 MAb (clone
JS-81) and the anti-SR-BI MAb CLA-1 were purchased from BD Biosciences.
The anti-SR-BI rat serum was generated as described previously (63). The
murine leukemia virus (MLV) gag-specific MAb was obtained from rat hybrid-
oma cells (CRL-1912; American Type Culture Collection).
Plasmid constructs and mutagenesis. The plasmid pUC-JFH1 carries the
full-length cDNA of HCV genotype 2a strain JFH1. The plasmid pUC-GND
JFH1 is identical except for the GND mutation in the NS5B-encoding sequence
(61). The plasmids used to generate HCV pseudoparticles (HCVpp) containing
the strain JFH1 envelope glycoproteins have been described previously (62).
Site-directed mutagenesis was carried out by using a QuikChange-II kit (Strat-
agene) according to the manufacturer’s instructions to introduce amino acid
substitutions at the target sites in E2. Briefly, the amino acid substitutions
N415D, T416A, N417S, G418D, and I422L in the E2-coding region were indi-
vidually introduced into the plasmid pUC-JFH1 using appropriate primers (the
sequences of which are available upon request). The presence of the desired
mutation in the resulting clones was confirmed by nucleotide sequencing the
DNA fragment between the BsiWI restriction site (nucleotides 1380 to 1386) and
the BsaBI restriction site (nucleotides 2597 to 2606). Sequences carrying the
appropriate mutation were subcloned back into pUC-JFH1 and the HCVpp
E1E2 expression vector using the restriction enzymes described above.
Generation of HCVcc virus. The JFH1 HCVcc was generated essentially as
described previously (61). Briefly, linearized plasmids carrying HCVcc genomic
cDNA were used as a template to generate viral genomic RNA by in vitro
transcription. Approximately 4  106 Huh-7 cells were added to a 0.4-cm Gene
Pulser cuvette (VWR) suspended in 400 l of phosphate-buffered saline (PBS).
Ten g of in vitro-synthesized RNA was then added and pulsed once at 960 F
and 270 V by using a GenePulser Xcell (Bio-Rad) electroporator. The trans-
fected cells were allowed to rest for 10 min before mixing them with fresh
medium and seeding them into tissue culture dishes. After incubation at 37°C for
the indicated time period, the medium containing the infectious virus progeny
was filtered through a 0.45-m-pore-size membrane before the infectivity was
determined as described below.
Determination of virus infectivity and RNA replication. To monitor wild-type
(WT) JFH1 replication during serial passaging, 5  106 naive Huh-7 cells were
infected in a T80 flask at a multiplicity of infection (MOI) of 0.005 in a total
volume of 10 ml. Subconfluent cells were split 1:10 into a new flask containing 24
ml of fresh medium. At each passage the cell culture supernatants were har-
vested, and their tissue culture 50% infective dose(s) (TCID50) were determined
by infection of naive cells, followed by immunostaining for NS5A as described
previously (35). To measure virus replication after electroporation, the cells were
transfected with viral transcript and seeded into 10-cm culture dishes. Fours
hours later, cells were treated with trypsin and split 1:3 into T25 flasks. After
incubation at 37°C for 72 h, culture supernatants were harvested, and the virus
titers were determined as described above. Total RNA was prepared from cells
by using an RNeasy kit (Qiagen), and the HCV RNA content was measured by
quantitative reverse transcription real-time PCR (qRT-PCR) as described pre-
viously (62). To measure virus replication postinfection, cells in six-well culture
dishes were infected at the indicated MOIs. After incubation at 37°C for 24, 48,
and 72 h, infectious virus yields in the medium and the intracellular viral RNA
levels were determined as described above.
Virus infectivity and replication were determined by using the focus-forming
assay (64) or the recently described reporter cell line, Huh7-J20 (23). For the
focus-forming assay, Huh-7 cells were fixed in methanol at 2 days postinfection
and immunostained for NS5A using MAb 9E10, and the HCV-positive foci were
counted by fluorescence microscopy to calculate focus-forming units (FFU) as
described previously (64). The Huh7-J20 cell line is engineered to release SEAP
reporter into the medium following HCV infection, thus enabling a rapid and
sensitive quantification of virus infectivity and replication (23). The SEAP activ-
ity in the medium was measured 72 h postinfection as described previously (23).
The effect of HDL on HCVcc infectivity was tested essentially as described
previously (59). Briefly, Huh7-J20 cells were preincubated for 2 h at 37°C in
medium supplemented with 3% lipoprotein-deficient fetal calf serum (LPDS).
The cells were then infected with WT or mutant HCVcc (generated in medium
containing 3% LPDS) in the presence or absence of 20 g of human HDL
(Athens Research Technology)/ml for 3 h at 37°C. Three hours later, the inoc-
ulum was replaced with normal medium, and the SEAP activity in the medium
was measured at 72 h postinfection.
Identification of cell culture adaptive mutations. Total RNA was prepared
from cells infected with virus collected from passage 9 cells (see Results) as
described above. RNA was converted to first-strand DNA by using a Superscript
III first-strand synthesis kit (Invitrogen) with the primer 5-TTGCGAGTGCC
CCGGGA-3. After digestion with 1 U of RNase H (Invitrogen) for 20 min at
37°C, one-quarter of the RT reaction was amplified with appropriate primers
that are available on request. The PCR products were gel purified by gel extrac-
tion (Qiagen) and used directly for sequencing.
HCVcc neutralization assays. Antibody inhibition assays were performed us-
ing either Huh-7 or Huh7-J20 cells, and virus infectivity levels were determined
by FFU or SEAP reporter assay, respectively, as described previously (23, 57).
Briefly, Huh-7 cells were plated out at a density of 3  103 per well in a 96-well
plate. For anti-E2 antibody neutralization assays, 50 FFU of virus was prein-
cubated at 37°C for 1 h with the appropriate inhibitory or control antibody prior
to infecting cells. To test neutralization by anti-receptor antibodies, cells were
preincubated with appropriate antibodies for 1 h at 37°C prior to infection with
50 FFU of the virus. At 3 h postinfection, the inoculum was replaced with fresh
medium and incubated for 48 h. The infectivity was determined as FFU following
immunostaining of the cells for NS5A as described above. The Huh7-J20 re-
porter cells were infected in the presence or absence of appropriate antibody
essentially as described above, and the virus infectivity levels were determined by
measurement of the SEAP activity released into the medium.
RNA interference. Two prevalidated small interfering RNA (siRNA) duplexes
(Applied Biosystems) targeting different regions of human CD81 (14501 and
146379) and SR-BI (s2650 and s2649) were used. The negative control siRNA
was composed of a scrambled sequence. Naive Huh-7 cells were transfected with
Lipofectamine RNAiMax (Invitrogen) and 50 nM siRNAs according to the
manufacturer’s protocol and incubated for 2 days prior to virus infection. The
efficiency of each gene knockdown at the time of infection was determined by
measuring the mRNA transcripts by qRT-PCR using TaqMan probes (ABI)
specific for SR-BI (Hs00969819) and CD81 (Hs00174717). In parallel, the cell
surface expression of each receptor was measured by incubating cells with the
anti-CD81 MAb (JS-81) or the anti-SR-BI MAb CLA-1, followed by an anti-
mouse IgG-fluorescein isothiocyanate (FITC) conjugated secondary antibody. A
subtype IgG1 was used as control. The cells were then analyzed by flow cytometry
in a FACSCalibur using CellQuest software (BD Bisociences). The cell viability
of siRNA-treated cells was measured by using the colorimetric WST-1 assay
(Roche), according to the manufacturer’s instructions.
HCVpp genesis, infection, and neutralization assays. HCVpp were generated
in HEK-293T cells, following cotransfection with plasmids expressing the MLV
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Gag-Pol and the MLV transfer vector carrying the firefly luciferase reporter
(kindly provided by F.-L. Cosset and J. Dubuisson, respectively), and HCV E1
and E2 as described previously (3, 57, 62). The medium containing HCVpp was
collected, clarified, filtered through a 0.45-m-pore-size membrane, and used to
infect the Huh-7 target cells. At 3 days postinfection, the luciferase activity in the
cell lysates was measured by using a Bright-Glo luciferase assay system (Pro-
mega). The levels of particle secretion were tested by immunoblotting for MLV
gag protein and E2 in the cell supernatants. For this, 10 ml of medium was
pelleted through a 20% sucrose cushion (wt/vol) in PBS at 116,000  g for 4 h.
Virus pellets were analyzed for HCV E2 and MLV gag by Western immuno-
blotting. For neutralization assays, HCVpp preparations were mixed with appro-
priate amounts of inhibitory or control antibody and incubated for 1 h at 37°C
prior to infection. To control the particle to antibody ratio, each pseudoparticle
inoculum was adjusted to the same level of infectivity. The percentage neutral-
ization was expressed relative to infection in the absence of antibody.
For immunoprecipitation of E1 and E2 glycoproteins, HEK-293T cells trans-
fected with the HCV glycoprotein-expressing plasmids were radiolabeled with
[35S]methionine and cysteine as described previously (47), and the labeled pro-
teins were immunoprecipitated using the anti-E2 human MAb CBH-5. The
immune complexes were subjected to SDS-PAGE, and the proteins were visu-
alized with a Bio-Rad Personal FX phosphorimager.
GNA and CD81 capture assay for E2 analysis. Galanthus nivalis agglutinin
(GNA)-capture enzyme-linked immunosorbent assays (ELISAs) to detect MAb
binding to E2 glycoprotein in lysates from electroporated Huh-7 cells were
performed essentially as described previously (48). Bound glycoproteins were
detected using the anti-E2 MAbs AP33, CBH-4B, and 3/11, followed by an
anti-species IgG-horseradish peroxidase-conjugated antibody and 3,35,5-tetra-
methylbenzidine (TMB) substrate. Absorbance values were determined at 450
nm after stopping the reaction with 0.5 M sulfuric acid. To assay E2-CD81
binding, E2 from cell lysates was captured onto an ELISA plate coated with
human CD81-LEL fused to glutathione S-transferase (hCD81-LEL), and the
bound E2 was detected using the anti-E2 human MAb CBH-4B as described
previously (11).
Isolation of MAb AP33 escape mutants. To isolate MAb AP33 neutralization
escape mutants, a selection protocol using a two-chamber cell culture system was
developed. JFH1WT RNA-electroporated Huh-7 cells were seeded into 1-m-
pore-size membrane of Thincert tissue culture inserts (Greiner), while naive
Huh-7 cells were grown into the lower compartment underside of the membrane.
To select for antibody neutralization escape mutants, MAb AP33 was added to
the medium at 100% neutralizing concentration. This system ensures that the
naive recipient cells are only infected via cell-free HCVcc that has escaped the
neutralizing concentration of AP33 and avoids infection with JFH1WT, thus
allowing rapid enrichment and propagation of antibody escape mutants. After
approximately 3 days, the infected recipient cells were treated with trypsin and
seeded in a fresh insert and placed in a well seeded with naive Huh-7 cells in the
medium containing the same neutralizing concentration of MAb AP33. This
process was repeated eight times. At each passage, the cells were collected for
analysis by immunofluorescence using MAb AP33 and the anti-NS5A antiserum
and to prepare total RNA from which the viral RNA was reverse transcribed,
and the resulting cDNA was PCR amplified and sequenced as described above.
Amino acid sequence analysis. A total of 1,311 full-length E2 protein se-
quences were downloaded from the HCV Sequence Database at Los Alamos
National Laboratory (http://hcv.lanl.gov). Sequences annotated as “bad” and
sequences containing obvious long frameshifts were excluded. Alignments were
performed by using MAFFT (26) and analyzed in MEGA (54).
RESULTS
Identification of a cell culture-adaptive mutation in E2. Na-
ive Huh-7 cells were infected at a low MOI with the HCV
JFH1WT virus generated from cells electroporated with viral
RNA and serially passaged over a period of 6 weeks (nine
passages). As shown in Fig. 1A, the infectious virus yields in
the culture supernatants increased up to cell passage 6 (cp6), at
which time the titers peaked at 105. Interestingly, 100-fold-
higher virus yields were obtained after infection of naive Huh-7
cells with the virus collected from cp9 (sp1). Sequence analysis
of the structural genes of the JFH1sp1 virus revealed a single
mutation in E2 (N415D) located within the highly conserved
region that represents an epitope for the broadly neutralizing
antibodies, MAb AP33, 3/11, e137, HCV1, and 95-2 (8, 45, 49,
56). Three recent studies have also reported adaptive E2 mu-
tations within this epitope, at positions T416 (10), N417 (52),
and I422 (27) (Fig. 1B). These were generated in Huh-7.5 cells
using the chimeric J6/JFH1 (T416A) or the WT JFH1 (N417S
and I422L) HCVcc. We examined the effect of these four
closely positioned mutations on JFH1 infectivity and antibody-
mediated neutralization.
Effects of E2 mutations on virus infection. The four E2
mutations were introduced individually into the JFH1 genome
by site-directed mutagenesis, and their effect on RNA replica-
tion and virus release after transfection in Huh-7 cells was
determined. In contrast to JFH1GND (which served as a neg-
ative control), both the WT and all E2 mutant virus RNAs
were replication competent (Fig. 2A). The released infectious
virus yield and intracellular RNA levels of all four mutants
were only slightly higher than WT, showing no significant dif-
ference at 72 h posttransfection.
We next determined the ability of mutant viruses to expand
in naive cells following infection. Extracellular virus collected
at 72 h posttransfection was used to inoculate naive Huh-7 cells
at an MOI of 0.1. At 24, 48, and 72 h postinfection, the
infectious virus released into the medium and the intracellular
viral RNA levels were determined. The infectious yield of each
mutant was found to be increased compared to the WT (Fig.
2B). Although the average values of each mutant were higher
than WT at 48 and 72 h, our statistical analysis found this not
to be significant (n  3; P  0.054, 0.171, 0.063, and
0.139, respectively, for mutants N415D, T416A, N417S, and
I422L; unpaired Student t test). The intracellular HCV RNA
FIG. 1. Determination of infectious virus yield during serial pas-
sage of infected cells. (A) Huh-7 cells were infected with the JFH1WT
at an MOI of 0.005 and serially passaged (cp) nine times. At each
passage, virus released into the medium was titrated by TCID50 assay.
Similarly, virus generated at passage 9 (sp1) was used to infect naive
Huh-7 cells, and the resultant infectious yield in the medium was
measured as described above. (B) The location of adaptive mutations
within the E2 residues 412 to 423 characterized in the present study.
The arrows denote amino acid substitution.
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levels in cells infected with the E2 mutants were unaltered
compared to the WT virus (Fig. 2C). Interestingly, the JFH1sp1
virus, which was included for comparison, produced infectious
titers 100-fold greater than WT at 72 h postinfection (data not
shown), indicating that this virus is better adapted likely due to
the presence of additional mutation(s) in the nonstructural
regions of the genome.
E2 mutations alter virus-receptor interactions. To establish
whether the mutations have altered the affinity of E2 for the
virus receptor CD81, a competition assay using the soluble
form of CD81 (hCD81-LEL) was performed. This protein has
been shown to interact with the E2 glycoprotein and inhibit
HCV infection (5). All four mutant viruses showed increased
sensitivity to neutralization by hCD81-LEL (Fig. 3A). To in-
vestigate whether this was due to a change in their affinity to
CD81, we tested the reactivity of the intracellular viral glyco-
proteins to hCD81-LEL. The levels of WT or mutant E2 in
Huh-7 cells transfected with appropriate viral RNAs was first
normalized by measuring their binding to the conformation-
sensitive anti-E2 human MAb CBH-4B (see Fig. S1a in the
supplemental material). Notably, the various E2s also bound
an anti-E2 MAb that recognizes a linear epitope with compa-
rable efficiency (see Fig. S1b in the supplemental material).
Consistent with the increased sensitivity of the viruses to
hCD81-LEL neutralization, the affinity of E2 mutants N415D,
T416A, and N417S to hCD81-LEL was enhanced in a dose-
dependent fashion (see Fig. S1c and S1d in the supplemental
material), by up to 38, 106, and 64%, respectively (Fig. 3b),
indicating an increased exposure of CD81 binding residues on
these mutant glycoproteins. However, for reasons that are un-
clear, the property of the E2 I422L mutant is at odds with this
hypothesis as it bound hCD81-LEL with comparable affinity to
WT E2 (Fig. 3B and see Fig. S1c and S1d in the supplemental
material). A potential explanation for the phenotype of E2
I422L is that some local change may occur during the virion
assembly process leading to a better exposure of the CD81-
binding region and therefore enhanced neutralization. Incuba-
tion of naive cells with anti-CD81 MAb prior to infection
showed no difference in inhibition of WT and mutant viruses
(Fig. 3C). This may be explained by the higher affinity of the
MAb outcompeting the binding of both WT and mutant virus
glycoproteins to cellular CD81.
Having established that these mutations influence the HCV-
CD81 interaction, we next investigated their effects on SR-BI-
dependent entry. Naive cells were preincubated with different
concentrations of a neutralizing anti-SRBI rat serum (63) prior
to infection with each virus. Interestingly, all mutants were less
sensitive than WT to neutralization by this antiserum (Fig. 3D
and Table 1). As expected, a control serum had no effect on
virus infectivity (data not shown). We next tested the effect of
HDL, an SR-BI ligand known to enhance HCV entry through
a process that requires the lipid transfer function of SR-BI (see
the introduction), on mutant virus infection. As shown in Fig.
3E, while the infectivity of WT was significantly enhanced, the
E2 mutants appeared insensitive to HDL treatment. Together,
these data suggest that each adaptive mutation alters HDL/
SR-BI-mediated uptake of the virus during entry.
To investigate the possibility of these mutants having re-
duced SR-BI dependency, two siRNAs targeting different re-
gions of SR-BI mRNA were transfected into Huh-7 cells to
silence its expression. At the time of infection, these cells
expressed 99% less SR-BI mRNA while maintaining 80% of
the control cell viability (Fig. 4A). The knockdown of cell
surface-expressed SR-BI was also confirmed by FACS analysis
(Fig. 4C). Under these conditions, the infectivity of all viruses
was inhibited by 94 to 98%, showing the E2 mutant viruses still
require sufficient expression of SR-BI for infection (Fig. 4B).
Similarly, efficient knockdown of CD81 reduced the infectivity
of all viruses (Fig. 4D to F).
E2 mutations alter sensitivity to neutralizing antibodies.
Previously, we reported a range of polyclonal anti-HCV IgGs
purified from HCV-infected patients that inhibited infection after
FIG. 2. Determination of infectious virus yield and replication.
(A) Huh-7 cells were electroporated with in vitro-transcribed viral
RNA. At 72 h posttransfection, virus released in the medium was
titrated by TCID50 (light gray bar) and intracellular RNA (black bar)
was quantified by qRT-PCR. Means and error ranges from duplicate
assays are shown. (B and C) Naive Huh-7 cells were infected at an
MOI of 0.1 with virus collected from the electroporated cells above. At
24 h (black bars), 48 h (light gray bars), and 72 h (dark gray bars)
postinfection, (B) the virus yield in the culture medium of infected
cells and (C) the intracellular viral RNA levels were determined by
TCID50 and qRT-PCR, respectively. Means and error ranges from
triplicate assays are shown.
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virus attachment to the cell (19). Here, the sensitivity of the WT
and the E2 mutant viruses to neutralization by two of these IgG
preparations (IgG17 and IgG19) was tested. The degree of inhi-
bition of the WT virus afforded by both of these IgGs was in
accordance with our previous findings (19). However, the mutant
viruses were more sensitive to neutralization, with IC50s 18- to
60-fold lower for IgG17 and 9- to 20-fold lower for IgG19 (Fig. 5A
and B; Table 1). It is noteworthy that these IgGs did not block
E2-CD81 interaction (data not shown). As expected, antibodies
purified from an uninfected individual (IgG20) had no effect on
virus infectivity (data not shown). We next tested the efficiency of
neutralization of all viruses by the conformation-sensitive anti-E2
human MAbs (HMAbs), CBH-5 and HC-11. Both of these
HMAbs recognize discontinuous overlapping epitopes within the
domain B of E2 and inhibit viral entry into cells by blocking the
E2-CD81 interaction (28–30, 46). We found that each mutant
virus was more sensitive to neutralization by these HMAbs com-
pared to JFH1WT, with the IC50s reducing by 12- to 30-fold for
CBH-5 and strikingly, by 3 to 4 log for HC-11 (Fig. 5C and D and
Table 1). Together, these results suggest that all four mutations
enhance the exposure of antibody neutralizing epitopes on the
virus particle.
FIG. 3. E2 mutants have altered affinity for CD81 and SR-BI. (A) JFH1WT (F), JFH1N415D (E), JFH1T416A (), JFH1N417S (‚), or JFH1I422L
(f) HCVcc was incubated with different concentrations of hCD81-LEL for 1 h prior to infecting target cells. At 2 days postinfection, virus
infectivity was determined by FFU assay. Percent neutralization was calculated by quantifying viral infectivity in the presence of hCD81-LEL
relative to standard infection. (B) The levels of WT or mutant E2 in Huh-7 cells transfected with appropriate viral RNAs was first normalized by
measuring their binding to the conformation-sensitive anti-E2 human MAb CBH-4B (see Fig. S1 in the supplemental material). Lysates containing
equivalent E2 were assessed for binding to hCD81-LEL by ELISA, and the data are presented as the averages of two independent experiments,
each performed in triplicate. (C and D) Naive Huh-7 cells were preincubated for 1 h with different amounts of antibodies against (C) CD81 or
(D) SR-BI before infection. Cells were then infected with 50 FFU of WT or mutant viruses (key to symbols as in panel A above) for 2 days, and
the infectivity levels were determined by FFU assay. The percent neutralization was calculated by quantifying viral infectivity in the presence of
inhibitory antibodies relative to a standard “no antibody” infection. (E) Huh7-J20 cells were infected with WT or mutant viruses in the presence
or absence of HDL and virus infectivity determined by SEAP assay as described in Materials and Methods. Error bars indicate standard deviation
from the mean (n  3; P  0.05, unpaired Student t test).
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We next measured the neutralization of these viruses using
the broadly neutralizing MAbs AP33 and 3/11, which recognize
distinct but overlapping epitopes within the highly conserved
region of E2 spanning residues 412 to 423 (QLINTNGSW
HIN) (56), where our four mutations are located. We found
that JFH1T416A and JFH1I422L were highly sensitive to neu-
tralization by both AP33 and 3/11, whereas JFH1N415D and
JFH1N417S were completely resistant (Fig. 6A and B, respec-
tively; Table 1). We next tested the reactivity of MAbs AP33
and 3/11 to each mutant E2 by ELISA. Normalized E2 from
transfected cell lysates was captured onto GNA coated plates
and probed with either AP33 or 3/11. Consistent with the
neutralization data, both AP33 and 3/11 showed very weak
binding to the E2 from JFH1N415D and JFH1N417S (Fig. 6C and
D). Together, the neutralization and ELISA data show that the
N415D and N417S mutations disrupt the binding of MAbs
AP33 and 3/11 to E2. However, while the reactivity of mutants
T416A and I422L to both MAbs was unaltered, they were
more sensitive to neutralization by these antibodies. The latter
phenotype is similar to what we observed in the hCD81-LEL
inhibition and binding assays (Fig. 3A and B), again supporting
the notion that local changes may occur to E2 during virion
assembly affecting neutralization. The increased sensitivity to
neutralization by the rodent MAbs (i.e., where the antibody
reactivity is not compromised) together with the heightened
inhibition of the mutant viruses to human antibodies described
above (Fig. 5) indicates that the mutations may induce global
conformational alterations in virion E2 allowing enhanced
epitope exposure.
Infectivity and neutralization profiling in HCVpp system.
We previously showed that T416A mutation in the HCV ge-
notype 1a strain H77 E2 abolished HCVpp infection (47).
However, the results presented here show that the same mu-
tation in the strain JFH1 HCVcc system does not affect infec-
tivity. To resolve this discrepancy, we assessed the infectivity of
the JFH1 E2 mutants in the HCVpp system. Although no
differences in infectivity was observed for WT and T416A in
HCVcc, we found a notable reduction in the infectivity of
HCVpp carrying the same mutations (Fig. 7A). Nevertheless,
neutralization assays using MAbs AP33 (Fig. 7C) and CBH-5
(Fig. 7D) showed that the effects of the mutations on antibody
reactivity were very similar in HCVcc and HCVpp (Table 1).
These data further support our notion that the mutations
within the amino acids 412 to 423 alter the conformation of E2
on the virus particle.
Using E2 GNA-capture ELISA, we confirmed that the WT
and the mutant E2 were expressed in comparable quantities
(not shown), and that the mutations affected neither the E2
incorporation into HCVpps nor the E1E2 heterodimer forma-
tion (Fig. 7A and B). Thus, the reasons for the lower infectivity
of mutant HCVpps are not clear. Several studies have demon-
strated functional differences between HCVpp and HCVcc. It
is conceivable that the former being a surrogate system may
not always mimic the authentic virus in terms of glycoprotein
presentation and function. Furthermore, HCVpp purely mea-
sure virus entry, excluding complications such as virus spread
and RNA replication that exist within the HCVcc system when
measuring virus infectivity. Therefore, direct comparisons in
infectivity between these two systems are not always appropri-
ate. This point is further strengthened by the observation that
the G451R adaptive mutation, which enhances HCVcc infec-
tion, renders HCVpps noninfectious (18).
Induced selection of a MAb AP33 escape mutant virus. The
cell culture adaptive E2 mutations characterized above oc-
curred in viral variants that emerged after prolonged passaging
of infected cells under standard tissue culture conditions. It is
intriguing that they each carry an amino acid substitution
within a highly conserved E2 region conferring significant phe-
notypic changes in relation to antibody neutralization and virus
entry. We sought to determine whether neutralization escape
mutants within the MAb AP33 epitope could be generated
under constant antibody selective pressure, and if so, whether
such mutants would be phenotypically similar to those arising
by spontaneous selection. JFH1WT virus was subjected to sev-
eral rounds of growth in the continuous presence of a neutral-
izing concentration of AP33 in the two-chamber Thincert tis-
sue culture system as described in Materials and Methods. The
antibody was excluded in a parallel control experiment. The
emergence of AP33 escape mutants was examined by dual
immunostaining, using MAb AP33 and the sheep anti-NS5A
antiserum, of naive cells infected with virus collected at each
round of selection. The infectious virus yield arising from cells
under antibody selective pressure was considerably lower dur-
ing the early passages compared to the control cultures. A
majority (90%) of the virus in these early round preparations
produced infectious foci in naive cells that were MAb AP33-
negative but anti-NS5A-positive in immunofluorescence assay
(data not shown). The proportion of the variant virus relative
to the WT virus increased at each round of selection, and
reached 100% by the eighth passage. Nucleotide sequence
analysis of the E1 and E2 coding region of the RT-PCR prod-
uct of early passage infected cell RNA revealed a single mu-
tation (G to D) in E2 at residue 418 (G418D), which remained
fixed throughout the passaging period. In contrast, no muta-
tions were found in the E1 and E2 coding regions of virus
passaged in parallel in the absence of MAb AP33.
The glycine at position 418 is one of the residues critical for
AP33 recognition (56). To verify that the G418D substitution
was responsible for the escape of AP33 neutralization, it was
introduced into the JFH-1WT genome. We then characterized
TABLE 1. IC50s of CD81-LEL and inhibitory antibodies
for each virus
Inhibitor
IC50 (g/ml)a
WT N415D T416A N417S G418D I422L
hCD81-LEL 50 4.4 3.4 3.7 2.0 3
Anti-CD81 0.12 0.1 0.13 0.07 0.12 0.13
Anti-SR-BI 1:560 1:40 1:25 1:20 1:170 1:100
IgG17 12.11 0.2 0.3 0.66 ND 0.3
IgG19 22 1.1 1.3 1.4 ND 2.5
IgG2 50 ND ND ND 1.2 ND
IgG4 50 ND ND ND 1.8 ND
CBH-5 0.6 0.02 0.02 0.05 0.12 0.035
AP33 1.5 NN 0.06 NN NN 0.12
HC11 7.0 0.001 0.0003 0.004 ND 0.002
3/11 44.9 NN 4.1 NN NN 7.12
AP33 (HCVpp) 1.0 NN 0.01 NN ND 0.02
CBH-5 (HCVpp) 2.3 0.01 0.016 0.03 ND 0.036
a NN, non-neutralizable; ND, not done. The anti-SR-BI IC50s are represented
as serum dilutions.
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FIG. 4. Silencing CD81 and SR-BI gene expression inhibits E2 mutant virus infection. Huh-7 cells were transfected with control siRNAs or
siRNAs targeting SR-BI (A to C) or CD81 (D to F). At 2 days posttransfection, the cell viability (gray bar) and mRNA expression levels (black
bar) of SR-BI (A) and CD81 (D) were measured by ELISA and qRT-PCR, respectively. The expression of SR-BI (C) and CD81 (F) on the surface
of Huh-7 cells transfected with control siRNAs (left panel) or receptor-specific siRNAs (right panel) was determined by FACS analysis as described
in Materials and Methods. Solid and broken lines represent cells stained with an anti-CD81 or anti-SR-BI antibody and IgG subtype control,
respectively. In parallel, the control siRNA-transfected Huh-7 cells (black bars) or the SR-BI (B) or CD81 (E) knockout cells (gray bars) were
infected with WT or mutant viruses and the intracellular HCV RNA levels measured by qRT-PCR to quantitate infectivity.
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the phenotype of the JFH1G418D virus in terms of virus infec-
tivity, receptor affinity, and antibody neutralization. Similar to
all of the adaptive mutants described above, the JFH1G418D virus
was more sensitive to neutralization by the patient IgGs, the
human anti-E2 MAb CBH-5 and soluble hCD81-LEL, and less
sensitive to inhibition by the anti-SR-BI antiserum (Fig. 8A and
Table 1). Furthermore, like JFH1N415D and JFH1N417S, this mu-
tant was resistant to neutralization by both MAbs AP33 and 3/11.
As with the adaptive mutants, the infectivity of JFH1G418D was
not drastically altered (data not shown).
Amino acid sequence analysis. We next investigated the
frequency of changes, if any, of the relevant E2 residues in
naturally occurring HCV isolates by sequence alignment. This
analysis showed that substitution from N to D at position 415
was very rare in naturally occurring sequences, being found in
only a single sequence among a sample of 1,311 full-length E2
protein sequences (Table 2). The substitutions from T to A at
position 416 and from N to S at position 417 were more
common, being found 13 and 17 times, respectively, within the
same sample. Position 416 was more generally variable, with
182 of the 1,311 sequences differing from this residue in the
JFH1 sequence. Position 418, in contrast, was extremely con-
served. Only 2 of 1,311 sequences varied from the G found in
JFH1, and neither of these has the G-to-D substitution pro-
duced here. The substitution from I to L at position 422 was
also rare, being found only five times.
Analysis of the total number of naturally occurring substi-
tutions at the relevant E2 positions identified the residue at
position 415 as the most variable in terms of number of resi-
dues used (eight in total), contrasting with the use of only G
and very rarely S at position 418 (Table 3). Although position
416 was the most likely to be substituted in naturally occurring
sequences with 182 substitutions found, it used fewer residues
than position 415. Position 422 had almost the same overall
number of substituted sequences as position 415 (38 versus 37)
but used a far lower number of residues (4 compared to 8).
DISCUSSION
In this study, we demonstrate that several mutations located
within a conserved E2 region encompassing residues 412 to 423
influence the viral glycoprotein interaction(s) with cell recep-
tors and neutralizing antibodies. This region carries residues
that are critical for recognition of two broadly neutralizing
antibodies used here, MAbs AP33 and 3/11 (45, 56). These
residues—L413, N415, G418, and W420 (AP33) and N415,
W420, and H421 (3/11)—are well conserved, which is relevant
for future vaccine design. However, this requires a better un-
derstanding of the epitope-antibody interaction at the struc-
tural level. In this respect, studies of viral variants that escape
antibody-mediated neutralization should provide useful infor-
mation and help identify the role of other residues in antigen-
antibody interaction.
Three of the five HCV JFH1 E2 mutations (N415D, N417S,
and G418D) described in the present study abrogated E2 re-
activity to, and virus neutralization by, MAbs AP33 and 3/11.
The N415D and N417S mutations arose spontaneously during
cell passaging, while the G418D was generated under AP33
FIG. 5. E2 mutant viruses have increased sensitivity to neutralization by human anti-envelope antibodies. JFH1WT (F), JFH1N415D (E),
JFH1T416A (), JFH1N417S (‚), or JFH1I422L (f) HCVcc was incubated for 1 h with different amounts of HCV-infected patient IgGs IgG17 (A) or
IgG19 (B), or the human MAbs CBH-5 (C) and HC-11 (D) prior to infection of target cells. The level of virus inhibition was assayed as described
in Materials and Methods. The percent neutralization was calculated by quantifying viral infectivity in the presence of anti-HCV glycoprotein
specific antibodies relative to infection in the absence of antibodies.
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selective pressure. Our amino acid sequence alignment shows
that N415D and G418D are extremely rare (1 and 0 occur-
rences, respectively, out of a sample of 1,311 sequences) in
natural sequences, whereas N417S, although by no means com-
mon, is the major naturally occurring variant (17 occurrences
of 27) (Table 2). Recently, we described a MAb AP33 neutral-
ization escape variant of a genotype 1a/2a chimeric HCVcc
following repetitive rounds of antibody neutralization and am-
plification in cell culture (17). This virus contained N415Y and
E655G mutations in the E2 glycoprotein. The N415Y mutation
alone severely attenuated MAb AP33 (and 3/11) recognition
and neutralization, but it did not enhance sensitivity to neu-
tralization by other human anti-E2 MAbs and, interestingly, it
substantially reduced viral fitness. Y at position 415 occurs 9
times in natural HCV sequences. Of the 37 variant residues at
this position (Table 3) it is the third most common, found in
genotypes 1a, 1b, 4b, and 6. In contrast, the N415D mutation,
although found much rarely in patient isolates, maintained
HCVcc fitness, as was the case for the other E2 cell culture-
adaptive mutations characterized in the present study. This is
likely due to the nature of the substituted amino acid and/or
genotypic differences in the E2 glycoprotein. The difference in
the E2 sequence could also account for the fact that the re-
petitive passaging of the genotype 2a JFH1 HCVcc in the
presence of a neutralizing concentration of MAb AP33 al-
lowed selection of a virus carrying the E2 G418D substitution.
However, the different selection protocols used between the
previous (17) and the present study may, at least in part, be
responsible.
We previously showed that alanine replacement of the res-
idue N417 in the HCV genotype 1a H77 E2 moderately re-
duced MAb AP33 and 3/11 binding (56). In the present study,
a change to serine at this position in the genotype 2a JFH1
strain drastically reduced AP33 and 3/11 binding, rendering
JFH1N417S HCVcc resistant to neutralization by either anti-
body and highlighting the contribution of N417 to their binding
sites on E2. Furthermore, the residue N417 is part of an N-
linked glycosylation site (22, 47), the removal of which from
genotype 1a E2 (N417Q) has been shown to increase the sen-
sitivity of HCVpp to antibody neutralization and to increase
CD81 binding (22). The latter observations are also in keeping
with our findings. Our data show that the molecular weight of
the genotype 2a E2 N417S mutant is identical to the WT
glycoprotein (Fig. 7b); however, it would be inappropriate to
conclude on this basis that this site is not used for glycosylation.
This is because the N417S change potentially creates a new N
glycosylation site over positions 415 to 417 (i.e., a change from
NTN to NTS, see Fig. 1b), which, if utilized, will not alter the
migration of the mutant E2 in SDS-PAGE. Clearly, further
studies are required to clarify this issue. The N417S change
occurs in 17 of the 27 variants at this position (Table 2),
suggesting that it may be naturally selected.
Bungyoku et al. (10) previously showed that the E2 T416A
mutation in a chimeric J6/JFH1 HCVcc background does not
FIG. 6. E2 mutations alter virus neutralization by MAbs AP33 and 3/11. JFH1WT (F), JFH1N415D (E), JFH1T416A (), JFH1N417S (‚), or
JFH1I422L (f) HCVcc was preincubated for 1 h with different concentrations of MAb AP33 (A) and 3/11 (B) before infecting target cells. The level
of virus inhibition was assayed as described in Materials and Methods. The percent neutralization was calculated by quantifying viral infectivity in
the presence of anti-E2 specific MAbs relative to infection in the absence of antibodies. (C and D) Reactivity of MAb AP33 or 3/11 to HCV E2.
WT or mutant E2 from electroporated Huh-7 cells was normalized as described in the legend to Fig. 3 and tested for reactivity to MAb (C) AP33
or (D) 3/11 by GNA-capture ELISA, and the data are presented as the averages of two independent experiments, each performed in triplicate.
Reactivity is expressed as the percentage of binding relative to the WT E2.
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alter virus infectivity in the Huh-7-derived sub line Huh7.5 (7).
In accordance with these data, we find here that the same
mutation has no significant affect on HCVcc spread in Huh-7
cells. Furthermore, we previously showed that the T416A mu-
tation in the genotype 1a HCVpp system moderately reduced
MAb AP33 and 3/11 recognition (56), enhanced CD81 bind-
ing, and abrogated pseudoparticle infectivity (47). In contrast,
we show here that this mutation in the genotype 2a JFH1
HCVcc enhances E2 reactivity to MAbs AP33 and 3/11 and
maintains WT virus infectivity. Together, the different infec-
tion systems, viral isolates and/or cell lines used in each study
likely account for these inconsistencies. T416A is one of seven
variants at a locus subject to positive selection (9), and al-
though occurring 13 times in our sample, is only a minor
component (7% of substitutions) of the extensive variability in
this position.
The I422L mutation was first isolated alongside other struc-
tural and nonstructural mutations after several rounds of JFH1
HCVcc passaging in Huh-7.5 cells and was shown not to alter
virus infectivity, which is in agreement with our findings in
Huh-7 cells (27). Consistent with our previous findings for
I422A (56), the I422L mutation did not affect E2 recognition
by MAbs AP33 and 3/11, confirming that this residue is not
critical for E2 recognition by either MAb. I422L occurs five
times in our sample of 1311 E2 sequences, constituting 13% of
the substitutions at this position (Table 2).
The reduced sensitivity of these mutants to inhibition by theFIG. 7. E2 mutations affect the infectivity conferred by E1E2 in the
HCVpp assay. (A) HCVpp bearing WT JFH1 E2 or mutant JFH1 E2
were generated in HEK-293T cells cotransfected with appropriate
constructs as described in Materials and Methods. Naive Huh-7 cells
were infected with HCVpp and infectivity was determined by measur-
ing luciferase levels (top panel). Sucrose cushion enriched HCVpp
preparations were Western blotted to detect virion incorporation of E2
using an anti-E2 MAb (middle panel) and MLV gag proteins using a
gag-specific MAb (bottom panel). (B) Immunoprecipitation of radio-
labeled E1 and E2 proteins expressed in HEK-293T cells was per-
formed using the anti-E2 HMAb CBH-5 as described in Materials and
Methods. (C and D) HCVpp bearing WT JFH1 E2 (F), JFH1 E2
carrying N415D (E), T416A (), N417S (‚), or I422L (f) mutation
were first normalized with respect to their infectivity (luciferase) values
and then mixed with MAbs AP33 (B) or CBH-5 (C) 1 h prior to
infecting Huh-7 cells. Virus infectivity was measured 3 days postinfec-
tion by quantifying luciferase activity. The percent neutralization was
calculated by quantifying viral infectivity in the presence of anti-E2
specific MAbs relative to infection in the absence of MAbs.
FIG. 8. Characterization of JFH1G418D virus. Huh7-J20 cells were
infected with the JFH1WT or JFH1G418D virus that had been preincu-
bated with different concentrations of IgG2 or IgG4, hCD81-LEL, or
the anti-E2 MAbs AP33, 3/11, or CBH-5. Alternatively, Huh7-J20 cells
preincubated with different concentrations of the anti-CD81 MAb or
an anti-SR-BI antiserum were infected with JFH1WT or JFH1G418D
virus. At 3 days postinfection the virus infectivity levels were deter-
mined by measuring SEAP activity in the culture medium. The results
are presented as the percent inhibition of JFH1G418D infection by the
indicated molecules at 50% inhibitory (IC50) concentrations for the
WT virus.
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anti-SR-BI antibody was an unexpected result. In keeping with
these observations, we found that all of the mutants studied
here were insensitive to HDL-mediated enhancement of virus
infection. The exact mechanism by which the HDL-SR-BI as-
sociation facilitates HCV entry is currently unknown. Al-
though no interaction between HDL and HCVpp particles has
been demonstrated in culture medium, the possibility of an
association occurring at a postbinding stage cannot be dis-
counted (58). More importantly, the binding of HDL to
HCVcc virions has yet to be investigated. Also, it has been
postulated that the lipid transfer events resulting from HDL-
SR-BI binding, known to be essential for regulating the prop-
erties of cells membranes, may affect the fusion efficiency of
the HCV envelope with cell membranes (58). SR-BI was first
identified as a putative HCV receptor based on its ability to
bind soluble, truncated E2 (sE2) via HVR1 (53). However, sE2
may not fully mimic E2 structures on the HCV virion (11, 28)
and an interaction between SR-BI and the E1E2 heterodimers
has yet to be confirmed. In addition, the initial binding of
serum HCV to SR-BI was found not to be mediated by HVR-1
or indeed other regions of the E2 glycoprotein. Instead, the
association of VLDL with virus particles appeared to play a
critical role in the primary interaction with SR-BI (40). Thus,
there is much uncertainty as to how HCV utilizes this receptor
during virus entry. In the absence of definitive assays that can
measure an interaction between SR-BI with full-length E1E2
or indeed HCVcc virions, it is difficult to decipher the effects
caused by our E2 mutations to the entry process via this re-
ceptor. However, the siRNA knockdown experiment shows
that SR-BI is not dispensable for the mutant virus entry.
Substitution of N415, T416, and N417 resulted in increased
E2-CD81 binding, whereas the binding of E2 I422L mutant to
CD81 was unaltered. Moreover, each mutant virus, including
JFH1G418D, exhibited a significantly greater sensitivity to neu-
tralization by hCD81-LEL, suggesting an increased affinity of
the mutated glycoproteins for CD81. This suggests that the
adaptive mutations improve the accessibility of CD81 binding
residues of the E2 present on mature virions. The heightened
inhibition of these mutants by a range of human anti-HCV
glycoprotein antibodies (and by the anti-E2 rodent MAbs
AP33 and 3/11 in the case of mutants T416A and I422L)
supports this theory.
Other studies have identified cell culture-adaptive mutations
within the E2 glycoprotein (13, 18, 65). In particular, the mu-
tation G451R has been extensively characterized (18, 65). This
single mutation increases the buoyant density of the virus, as
well as its ability to bind CD81. G451R also reduces SR-BI
dependency and increases virus sensitivity to neutralization by
E2 specific antibodies, indicating the greater availability of
epitopes on the mutant particle. The mutations characterized
in the present study have very similar phenotypes to G451R,
suggesting that the E2 mutations selected in HCVcc may have
arisen in response to similar selective pressures. For example,
to persist during long-term culture subtle alterations to E2
conformation may enhance virus-receptor interactions and
maintain spread. In line with this, it has been shown that
during persistent infection of JFH1 in cell culture certain cell
populations emerge that are less permissive to HCV infection
due to a decrease in the cell surface expression of CD81 (65).
Although this possibility was not investigated in our study or
the others (10, 27, 52), the increased affinity of each mutant to
TABLE 2. Naturally occurring substitutions in 1311 HCV E2 protein sequences
Position JFH1residue Variant
a No.b Totalc Prop.d Accession no. (genotype)e
415 N D 1 37 0.03 EU482838 (1a)
416 T A 13 182 0.07 AY956468 (1a), AY958005 (3a), EU155215 (1a), EU155249 (1a), EU155282 (1a),
EU155285 (1a), EU155288 (1a), EU155379 (1a), EU255930 (1a), EU255980
(1a), EU482845 (1a), EU482836 (1a), EU643835 (6)
417 N S 17 27 0.63 EU256046 (1a), EU256031 (1a), EU255964 (1a), EU255952 (1a), EU255943 (1a),
EU155354 (1a), EU155347 (1a), EU155297 (1a), EU155274 (1a), EU155215
(1a), EF407468 (1b), EF407466 (1a), EF407477 (1a), EU407415 (1a),
EF026073 (2/5 natural recombinant), AY957988 (3a), AM408911 (2/5)
418 G D 0 2 0.00
422 I L 5 38 0.13 AB047643 (2a), AF271632 (1a), FJ828970 (1a), FJ828971 (1a), M62321 (1a)
a That is, substitutions as described in the text.
b That is, the total number of sequences in a sample of 1,311 HCV E2 proteins with the same substitution.
c That is, the total number of substituted residues in the sample of 1,311 (see Table 3).
d Prop., the proportion of naturally occurring substitutions that are identical to the substitutions produced in the present study.
e The accession number(s) of HCV sequences (genotypes are shown in parentheses) carrying the relevant variant is listed.
TABLE 3. Total number of naturally occurring substitutions in
1,311 HCV E2 protein sequences
Protein sequence
Residue at position:
415 416 417 418 422
JFH1 N T N G I
Variantsa K N S S L
1 Y S D V
2 H A H T
3 S I G
4 T K T
5 R R
6 D
Total no.b 37 182 27 2 38
a Substitutions occurring in the sample of 1,311 E2 protein sequences.
b Total number of sequences with a substitution. Position 416 is the most
polymorphic in terms of total number of substitutions at 14% (182 in 1,311
sequences). However, position 415 has a greater diversity of variants (8 amino
acids used at least once, despite only 37 substitutions).
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CD81 (Fig. 3) may assist viral spread in cells presenting less
CD81.
The E2 region studied here lies immediately C-terminal to
the HVR-1, in which positive selection is active. In contrast,
the region of interest has only a single site detected as posi-
tively selected—that at position 416 (9). Consistent with this,
the survey of 1311 E2 sequences reported here shows that 182
of them are variants (ca. 14%) at position 416. At the remain-
ing sites of interest, substitution is much rarer, never higher
than 4% of the total sample (Table 3). In addition, the specific
mutations described here occur relatively rarely in natural
HCV sequences (Table 2). For instance, the G-to-D change at
position 418 is not found at all in our sample of 1,311 se-
quences. Indeed, this position is extremely conserved, with
only two substitutions found in the full-length E2 sequences
sampled (Tables 2 and 3). Both of those substitutions are G to
S and occur in closely related sequences (not shown). The
N415D change is similarly very rare in our sample, occurring
only once.
The I-to-L substitution at position 422 is also rare (Table 2).
Where substitution does occur naturally at position 422, it is
confined to relatively hydrophobic residues (Table 3), suggest-
ing that a selective constraint for hydrophobicity applies at this
position. In contrast, the N417S change constitutes 63% of all
variants found at that position, occurring 17 times (Table 2).
The T416A change is intermediate in frequency, constituting
7% of all naturally occurring substitutions at that position. The
naturally occurring variants at all positions are found in a wide
range of genotypes (Table 2). For instance, position 416 has T
to A substitution in genotypes 1a, 3a, and 6 and position 417
has N-to-S substitutions in 1a, 1b, 3a, and 2/5 recombinants.
The substitutions produced in the present study at positions
415 to 417 and 422 are spontaneous occurrences in long-term
cell passage, where selective conditions may be very different
to those found in the natural host. This is a plausible explana-
tion for the relative rarity of these substitutions in naturally
occurring sequences.
Broadly neutralizing MAbs to this conserved region hold
great promise as therapeutics. Moreover, the epitope recog-
nized by these MAbs can be considered a valid lead for future
vaccine design. However, an in-depth understanding of how
the neutralizing antibodies interact with E2 is necessary, for
both effective vaccine design and understanding the role of the
epitope in receptor interaction and virus entry. An additional
challenge for vaccine design is the emergence of viral variants
during the course of infection that escape antibody neutraliza-
tion. In vivo, the prevalence of antibodies reactive to the E2
region 412-423 (QLINTNGSWHIN) is 2.5% (55). There-
fore, there is no great selective pressure acting on this region
driving the emergence of neutralization escape mutations. If
such mutants do arise spontaneously, they are likely to confer
either reduced virus fitness (17) or an increased vulnerability to
neutralization by circulating antibodies targeting various glyco-
protein regions, thereby eliminating these variants from the
virus pool. In summary, our data contribute to further defining
the role of key residues within the HCV E2 412-423 region that
influence virus-receptor interactions and antibody-mediated
neutralization.
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